Ligand Pharmaceuticals - Biopharmas Technology and Capital Partner Ligand invests in the clinical development and commercialization of high-value medicines We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development stage programs
Ligand Pharmaceuticals Incorporated - Investor Relations Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world
Ligand Reports First Quarter 2025 Financial Results Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines Ligand does this by providing financing, licensing our technologies or both
Royalty Portfolio - Ligand Pharmaceuticals Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered commercial and development-stage programs
Ligand Pharmaceuticals Incorporated - Ligand Reports Third Quarter 2025 . . . For more information, please visit www ligand com Follow Ligand on X and LinkedIn We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD
Ligand Pharmaceuticals Incorporated - Stock Info All 3m NASDAQ:LGND News Releases Sep 15 Sep 22 Sep 29 Oct 6 Oct 13 Oct 20 Oct 27 Nov 3 Nov 10 Nov 17 Nov 24 Dec 1 Dec 8 2020 2021 2022 2023 2024 2025 140 160 180 200
Ligand and Medtronic Commit $70 Million in Strategic Capital to . . . Ligand’s decision to invest in our partnered programs and our team reflects our shared conviction in the transformative potential of both AVIM therapy and Virtue SAB—our late-stage flagship technologies aimed to address important unmet medical needs in large, established global markets